Investigational Drug Information for GSK3640254
✉ Email this page to a colleague
What is the drug development status for GSK3640254?
GSK3640254 is an investigational drug.
There have been 15 clinical trials for GSK3640254.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 31st 2019.
The most common disease conditions in clinical trials are HIV Infections, Infections, and Immunologic Deficiency Syndromes. The leading clinical trial sponsors are ViiV Healthcare, GlaxoSmithKline, and [disabled in preview].
There are nine US patents protecting this investigational drug and eighty international patents.
Summary for GSK3640254
| US Patents | 9 |
| International Patents | 80 |
| US Patent Applications | 33 |
| WIPO Patent Applications | 6 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2019-01-31) |
| Vendors | 10 |
Recent Clinical Trials for GSK3640254
| Title | Sponsor | Phase |
|---|---|---|
| A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults | ViiV Healthcare | Phase 2 |
| A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants | ViiV Healthcare | Phase 1 |
| A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults | ViiV Healthcare | Phase 2 |
Clinical Trial Summary for GSK3640254
Top disease conditions for GSK3640254
Top clinical trial sponsors for GSK3640254
US Patents for GSK3640254
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GSK3640254 | ⤷ Start Trial | Triterpenoids with HIV maturation inhibitory activity | VIIV HEALTHCARE UK (NO. 4) LIMITED (Brentford, Middlesex, GB) | ⤷ Start Trial |
| GSK3640254 | ⤷ Start Trial | C-3 and C-17 modified triterpenoids as HIV-1 inhibitors | ViiV Healthcare UK No 5 Ltd , Bristol Myers Squibb Co | ⤷ Start Trial |
| GSK3640254 | ⤷ Start Trial | Triterpenoids with HIV maturation inhibitory activity | ViiV Healthcare UK No 4 Ltd | ⤷ Start Trial |
| GSK3640254 | ⤷ Start Trial | C-3 and C-17 modified triterpenoids as HIV-1 inhibitors | ViiV Healthcare UK No 5 Ltd , Bristol Myers Squibb Co | ⤷ Start Trial |
| GSK3640254 | ⤷ Start Trial | Triterpenoids with HIV maturation inhibitory activity | ViiV Healthcare UK No 4 Ltd | ⤷ Start Trial |
| GSK3640254 | ⤷ Start Trial | Diacylglycerol kinase modulating compounds | Carna Biosciences Inc , Gilead Sciences Inc | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GSK3640254
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GSK3640254 | Argentina | AR101077 | 2034-04-11 | ⤷ Start Trial |
| GSK3640254 | Australia | AU2015243500 | 2034-04-11 | ⤷ Start Trial |
| GSK3640254 | Brazil | BR112016023414 | 2034-04-11 | ⤷ Start Trial |
| GSK3640254 | Canada | CA2944778 | 2034-04-11 | ⤷ Start Trial |
| GSK3640254 | Chile | CL2016002528 | 2034-04-11 | ⤷ Start Trial |
| GSK3640254 | China | CN106604909 | 2034-04-11 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
